Israel Active

Israeli ex-supermodel Michaela Bercu featured previously when she founded the app Tribu, which connects volunteering needs with those who wish to help. She recently completed the Magen David Adom paramedic course, and works two 8-hour shifts a week as a medical orderly.

Magen David Adom and Israel Railways are installing defibrillators, for the first time, on more than 150 Israeli passenger trains to save lives in the event of cardiac issues. They have already equipped defibrillators at all 67 active Israeli train stations.

UK Telegraph journalist Isabel Oakeshott accidentally went over the handlebars of her e-scooter in Tel Aviv. But she was over the moon about her treatment at the state of the art Sylvan Adams Emergency Hospital (see previously) at Tel Aviv’s Sourasky (Ichilov) Medical Center.

Israel’s IceCure (see previously) is already saving many lives by destroying tumors using cryoablation (freezing).  Its most recent ICESECRET study on 114 kidney cancer patients with small renal masses (SRM) showed an 88.7% non-reoccurrence rate.

A new study from Tel Aviv University found that diagnoses and treatment recommendations given by AI were more accurate than those of physicians. Of 461 online patient visits, AI was rated as good in 77% of cases but only 67% by doctors. Bad AI ratings were 2.8%; Bad doctors were at 4.6%.

Israeli medical emergency NGO United Hatzalah has just completed training it Psycho-trauma Canine Unit. Its 10 special dogs provide support until the ambulance arrives. Leading Israeli pet supply chain, Speedog, will donate a portion of sales proceeds, plus essential equipment and food.

Santiago, a baby from Guatemala born with a cleft lip and palate (and other problems), successfully underwent complex corrective surgery at Israel’s Schneider Children's Medical Center. The parents knew in advance of Santiago’s condition and arranged to have their baby in Israel.

The radiation treatment from Israel’s Alpha Tau (see previously) has been used to treat skin cancer, prostate cancer, pancreatic cancer, liver cancer, and lung cancer. It now has had US FDA approval to initiate a trial for patients with recurrent glioblastoma (brain cancer).

A team led by Hebrew University of Jerusalem researchers has developed the first ever blood test capable of detecting Parkinson’s disease, even before symptoms emerge. The test identifies transfer RNA fragments unique to the neurodegenerative disease.

Israel’s Silexion Therapeutics reported that its SIL-204 pancreatic cancer treatment effectively reduces primary tumor growth and secondary cancer spread. Silexion 's first generation LODER treatment already had good results in Phase 2 trials on “simple” cancers.